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INTRODUCTION
The association between cancer and inflammation has 
been recognized for over 2 000 years[1,2]. Virchow rec-
ognized that many tumors arise in a setting of  chronic 
infl ammation, and later, Dvorak aptly described cancer as 
“wounds that do not heal”[3]. It is estimated that up to 15% 
of  cancers worldwide are associated with chronic infec-
tion[4] and there are many more examples throughout the 
body of  cancer associated with infl ammation of  unclear 
etiology. Within the GI tract, examples include esophageal 
adenocarcinoma arising in the setting of  Barrett’s meta-
plasia, gastric cancer occurring secondary to Helicobacter 
infection, colorectal cancer occurring in longstanding in-
flammatory bowel disease and hepatocellular carcinoma 
secondary to viral hepatitis (Table 1). There are several 
mechanisms by which infl ammation and a cycle of  chronic 
injury/repair has been postulated to lead to cancer, includ-
ing the push for continued proliferation, an abnormal 
inflamed-stromal environment, and more recently we 
recognize a role for engraftment of  circulating marrow-
derived stem cells, which may contribute to the stromal 
components of  the tumor as well as the epithelial compo-
nent of  the tumor mass itself.
INFLAMMATION: THE RELATIONSHIP 
BETWEEN TISSUE INJURY, REPAIR AND 
CANCER
Proliferation of  cells alone is not suffi cient to cause cancer, 
rather proliferation in the setting of  altered growth signals 
from inflammatory cell infiltrates and DNA damaging 
agents released from infiltrating leukocytes promote 
malignant degeneration. Wound healing, which requires 
subversion of  usual growth programs, mobilization and 
migration of  cells and a heightened resistance to apoptosis, 
embodies all the properties of  malignant cells with one 
exception, that is, healing is self  limited. Successful 
wound healing results in restoration of  tissue integrity 
and resolution of  inflammation, reinstating homeostatic 
growth control. The tissue environments of  longstanding 
unrelenting chronic infection or idiopathic chronic 
inflammation are persistent states of  inadequate wound 
healing. Within this setting, inflammatory cells produce 
highly reactive oxygen and nitrogen species, which interact 
with cellular DNA inducing point mutations, deletions or 
rearrangements. Usually DNA damage such as this triggers 
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Abstract
Cancer commonly arises at the sites of chronic infl am-
mation and infection. Although this association has long 
been recognized, the reason has remained unclear. With-
in the gastrointestinal tract, there are many examples 
of infl ammatory conditions associated with cancer, and 
these include refl ux disease and Barrett’s adenocarcino-
ma of the esophagus, Helicobacter infection and gastric 
cancer, infl ammatory bowel disease and colorectal cancer 
and viral hepatitis leading to hepatocellular carcinoma. 
There are several mechanisms by which chronic infl am-
mation has been postulated to lead to cancer which 
includes enhanced proliferation in an endless attempt to 
heal damage, the presence of a persistent infl ammatory 
environment creating a pro-carcinogenic environment 
and more recently a role for engraftment of circulating 
marrow-derived stem cells which may contribute to the 
stromal components of the tumor as well as the tumor 
mass itself. Here we review the recent advances in our 
understanding of the contributions of circulating bone 
marrow-derived stem cells to the formation of tumors in 
animal models as well as in human beings.
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apoptosis. However, in areas of  chronic inflammation 
and repair, growth programs are corrupted and the 
environment is poised to allow replication and survival 
of  cells, which under normal situations would either be 
quiescent or lost to apoptosis. Allowing cells to continually 
divide in an environment conducive to DNA damage 
may result in the accumulation of  genetic defects and the 
emergence of  malignant cells.   
Which cell is the target of  malignant transformation 
has been the area of  much debate. Original thought was 
that a terminally differentiated cell would acquire enough 
genetic damage to replicate endlessly. This would require 
multiple genetic alterations in key cell signaling cascades 
to allow autonomous growth. A more likely scenario, 
however, is that these cells would undergo apoptosis or 
be sloughed off  as a normal part of  organ turnover prior 
to “backing up” the differentiation ladder sufficiently to 
acquire independent growth. More recently, focus has 
been on tissue-derived stem cells as the source of  cancer. 
Tissue stem cells possess several important features mak-
ing them attractive candidates for malignant degeneration. 
These include long life span, relative apoptosis resistance 
and ability to replicate for extended periods of  time. In the 
setting of  chronic infl ammation, progenitor or stem cells 
within the peripheral tissue are forced to undergo multiple 
rounds of  cell division predisposing to the accumulation 
of  mutations. While restricted progenitors or even differ-
entiated cells can still become transformed, in most cases, 
it has been believed that early stem cells are the targets of  
transformation.
If  one looks at areas of  high proliferative capacity (high 
BrdU or PCNA staining in tissue) as the stem cell zone, 
then this theory of  peripheral stem cells as the cells of  
origin of  cancer must be reconciled with the fact that this 
supposed stem cell compartment is often the most dam-
aged and depleted by agents thought to be carcinogens[5]. 
With chronic inflammation leading to atrophic changes 
attributed to peripheral stem cell exhaustion, the very cell 
thought to be transformed is lost - leading us to investigate 
if  an alternate stem cell compartment is responsible for 
peripheral cancers arising in the setting of  infl ammation. 
In order to understand this concept, and why the bone 
marrow-derived stem cell (BMDC) is a “logical choice” 
for a cancer stem cell, we need to understand a few points 
about cancer stem cells, and BMDCs in general. 
Stem cells in cancer - cancer as an abnormal organ
A tumor mass can be compared to an abnormal organ; 
in that it is composed of  a heterogeneous mixture of  cell 
types and of  cells possessing different proliferative capaci-
ties and different levels of  differentiation. Tumor cells are 
admixed with fi broblasts, endothelial cells and infl amma-
tory cells comprising the tumor stroma. This tumor stroma 
is being increasingly recognized as a critical contributor to 
malignant growth and survival of  the tumor mass; how-
ever, stromal cells themselves are usually not malignant. 
Likewise, not all cells within a tumor are malignant - mean-
ing not all cells can form tumors if  transplanted at another 
site, or into a secondary host. In fact, the majority of  cells 
within a tumor are incapable of  independent growth and 
are readily susceptible to apoptosis. Only a small frac-
tion of  cells within a tumor are capable of  independent 
growth, and fulfi ll the criteria described for cancer stem 
cells[6-8]. These cells have metastatic potential, form tumors 
in secondary hosts and are believed to be responsible for 
continual renewal of  cells within the tumor mass. These 
cells are likely to proliferate slowly and asymmetrically, 
Cause              Site
Chewing tobacco/oral irritation                      Oral cancers
Smoking/chronic bronchitis                   Lung   
Asbestos                                                         Mesothelioma  
Refl ux disease                                                    Barretts’ adenocarcinoma of  
                     the esophagus    
Chronic Helicobacter infection                   Gastric adenocarcinoma and 
                     lymphoma
Chronic pancreatitis                                       Pancreatic cancer
Opisthorchis sinensis infection (liver fl uke)   Cholangiocarcinoma
Viral hepatitis                                 Hepatocellular carcinoma
Ulcerative colitis and Crohn’s disease             Colorectal carcinoma
Human papilloma virus                   Anogenital carcinomas
Schistosomiasis                    Bladder cancer
Pelvic infl ammatory disease                    Ovarian cancer
Chronic osteomyelitis                    Osteosarcoma
Chronic scar tissue                                    “Scar” cancer arising in the 
                     lung, skin and other areas of  
                     scarring 
Table 1 Infection and infl ammation associated with cancers
High proliferation rate
Quiescent
→→
→→
→→
→
→→
→
→
→
Figure 1 A proposed model for the cancer stem cell. The cancer stem cell repli-
cates itself asymmetrically, thus maintaining one daughter stem cell identical to 
itself. This remains in a relatively quiescent state. The asymmetric division also 
produces another daughter cell with a high proliferative rate which rapidly divides 
to sustain the tumor mass.
Rapidly growing cells killed
Stem cell remains
Re-growth of tumor
Tumor growth
and metastasis
Conventional
Chemotherapy→ →
Targeted
chemotherapy
Stem cell killed
Residual cells can not
Sustain tumor mass
Apoptosis or
differentiation→ →
Figure 2 Conventional versus stem cell-targeted chemotherapy. Conventional che-
motherapy and radiotherapy targets rapidly dividing cells, and may shrink tumor 
mass substantially. However, the stem cell (gray), which is relatively quiescent, is 
not affected. Regrowth of tumor from surviving stem cell leads to regrowth of tumor 
and treatment failure. Chemotherapy targeted at the stem cell would remove the 
source of new cell growth, and allow residual cells within the tumor to be targeted 
with chemotherapy, differentiating agents or therapy aimed at inducing apoptosis, 
thus successfully eliminating the tumor.
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self  renewing the stem cell population and giving rise to 
daughter cells, which proliferate to sustain tumor growth 
(Figure 1). Conventional anti-cancer chemotherapy and 
radiotherapy target rapidly dividing daughter cells, affect-
ing the bulk of  the tumor mass, but leave the cancer stem 
cell intact, explaining the often rapid recurrence of  tumor 
bulk, once therapy is stopped (Figure 2). At present, the 
most pressing issue for cancer research is to identify the 
cancer stem cell and exploit its unique characteristics with 
targeted therapies. 
Bone marrow stem cells
BMDCs are a heterogenous group of  cells isolated from 
the bone marrow which are capable of  repopulating the 
hematopoietic system of  a lethally irradiated immunologi-
cally compatible secondary host. These cells have been di-
vided into at least two main categories; the hematopoietic 
and mesenchymal stem cells (MSC). Hematopoietic stem 
cells are traditionally regarded as the cells which give rise 
to the formed elements of  the blood and have been used 
extensively in human bone marrow transplantation. Thus, 
hematopoietic stem cells have been extensively studied and 
defi ned with regard to surface markers, growth character-
istics and repopulation potential[9]. Less well defined are 
the MSC. This term MSC, as defi ned in the literature, is 
the heterogenous population of  cells isolated as the adher-
ent population, when total marrow is placed in culture[10]. 
These cells give rise to adipocyte, chondrocyte, cells of  
osteocyte lineages and the marrow mesenchyma, which is 
vital for optimal hematopoiesis[11-13].  
Work from multiple laboratories demonstrates sur-
prising roles for marrow-derived stem cells in addition to 
hematopoiesis, stressing that the potential for differentia-
tion may be much greater than originally believed. Markers 
defining cell subpopulations within the marrow are not 
standardized in these studies, making direct comparison of  
data between laboratories challenging; however, one thing 
remains consistent - cells within the bone marrow have a 
markedly greater differentiation potential than originally 
believed. For the purposes of  this discussion, the term 
BMDCs will be broadly used to refer to cells derived from 
the marrow, and will encompass hematopoietic stem cells, 
MSC multipotent progenitor cells and whole marrow.
In vitro and in vivo studies-plasticity of BMDCs
Multiple and elegant studies from independent groups 
have shown quite clearly that bone marrow stem cells can 
differentiate along multiple diverse lineage pathways[14-17]. 
These fi ndings challenge the conventional view that bone 
marrow stem cells give rise only to the marrow mesen-
chyma or formed elements in the peripheral blood. In vitro, 
BMDCs have been shown to differentiate at the single cell 
level and acquire characteristics of  mesoderm, neuroecto-
derm and endoderm[15,16]. These cells appear to use culture 
environmental factors to guide lineage decisions. Strik-
ingly, in vivo studies in the mouse model have confi rmed 
this plasticity. Elegant studies utilizing transplanted single 
cells demonstrate differentiation along multiple lineages, 
supporting a central role for the local tissue environment 
in dictating differentiation of  stem cells, confi rming that 
a single cell is multipotent, and supporting the assertion 
that experimental fi ndings demonstrating multiple cell lin-
eage differentiation is not due to circulating tissue specifi c 
progenitor cells, but rather to a single multipotent cell. In 
these studies, multiple types of  epithelial cells have been 
shown to be derived from BMDCs including epithelium 
of  the lung, gastrointestinal tract and skin after transplan-
tation of  a single bone marrow-derived stem cell[14]. This is 
not a transient event, as cells can be recovered nearly a year 
after transplantation. In the gastrointestinal tract, engrafted 
cells are seen as isolated epithelial cells in the gastric pits 
of  the stomach, the small intestinal villi, the colonic crypt, 
and rarely in the esophagus. Under these experimental 
conditions, cells were recovered as single differentiated 
epithelial cells, and did not appear to engraft into the stem 
cell niche as clonal expansion was not seen. Infusion of  
labeled BMDCs into a non-irradiated host, also led to the 
engraftment (albeit to a lesser degree) and differentiation as 
epithelial cells of  the liver, lung and gut in a similar pattern 
to that seen with marrow ablation and transplantation[15], 
demonstrating that engraftment and differentiation are 
true physiological events and not merely artifacts of  ir-
radiation and experimental manipulation. While epithelial 
cell damage is not necessary for engraftment, studies sup-
port the notion that damage to the epithelium increases 
engraftment.  
The mechanism by which the marrow-derived cells 
acquire the appropriate phenotype of  epithelial cells is not 
known, with evidence supporting both direct differentia-
tion or fusion with a peripheral cell[18-21]. The method of  
engraftment and differentiation may be specific to the 
individual tissues and/or may depend on the mechanism 
of  injury inducing engraftment. Irrespective of  the mecha-
nism involved, BMDCs have been shown to engraft and 
take on the function of  cells within the peripheral tis-
sues[18-24]. 
HUMAN STUDIES - EVIDENCE FOR 
PLASTICITY OF BMDCS IN PATIENTS 
T R A N S P L A N T E D W I T H G E N D E R 
MISMATCHED BONE MARROW 
Human studies have confi rmed that plasticity of  BMDCs 
is not restricted to mice, and may be a physiologically 
relevant phenomenon in man as well. Studies, examin-
ing peripheral tissue of  female patients transplanted with 
bone marrow derived from male donors, have shown that 
BMDCs from the donor can differentiate into skin, gut 
epithelium and mature hepatocytes[25,26]. Identifi cation of  
the Y chromosome in cells of  these tissues confi rms that 
BMDCs can substantially repopulate the GI tract epithe-
lium[26], and this repopulation does not appear to be a rare 
event. Patients in these studies have some level of  graft-
versus-host disease, and the level of  infl ammation in the 
tissue correlates with the level of  donor cell engraftment. 
These fi ndings are consistent with the data derived from 
murine studies and suggest the infl ammatory environment 
is crucial for optimal engraftment and differentiation of  
BMDCs. The fact that BMDCs have the capacity to dif-
ferentiate along organ-specifi c lineages appropriate for the 
organ of  engraftment, and are found in increasing num-
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bers during chronic infl ammation (a condition associated 
with cancer), places these cells “in the right place, at the 
right time” to be candidates for the cancer stem cell.  
Similarities between BMDCs and cancer cells 
In addition to what appears to be of  immense plasticity 
of  cells within the bone marrow, BMDCs have other traits 
which make them attractive candidates for cancer stem 
cells.  BMDCs have the capacity for self  renewal, are long 
lived, are chemoresistant, and may be inherently muta-
genic[27-30]. Intriguing is the fact that similar growth regula-
tors and control mechanisms are involved in both cancer 
and stem cell maintenance. For example, proteins from the 
polycomb group, the epigenetic chromatin modifi ers, are 
involved in both cancer development and maintenance of  
embryonic and adult stem cells[31]. Also, pathways used by 
bone marrow stem cells for trafficking appear to be ex-
ploited by tumor cells for metastasis[32]. For instance, che-
mokines and cytokines produced during chronic inflam-
mation (such as SDF-1) infl uence the behavior and migra-
tion of  cancer cells. These are the same chemokines and 
cytokines responsible for physiological stem cells homing 
back to the marrow cavity[33-37]. Identification of  bone 
marrow stromal cell-derived growth inhibitor as a potent 
inhibitor of  breast cancer cell migration, and the capability 
of  this protein to induce cell cycle arrest and apoptosis in 
breast cancer stem cells further supports the use of  simi-
lar growth mechanisms between stem and cancer cells[38]. 
Infl ammation of  the GI tract is associated with IL-6 and 
IL-8 production which initiate neutrophil infiltration[40]. 
Interestingly, IL-6 is also chemotactic for MSC[34]. Other 
cytokines and chemokines prominent in the setting of  
mucosal infl ammation such as VEGF and MIP-1α are also 
chemoattractants for MSC[34,35]. Receptors such as CXCR 
2 and 4 are found on both cancer cells and stem cells, and 
infl uence the homing of  stem cells, or invasion/metastases 
of  cancer cells, suggesting a link between the two popula-
tions of  cells. One might suppose that a mechanism simi-
lar to that used to regulate BMDC circulation and homing 
back to areas of  bone may also facilitate migration and 
engraftment of  BMDCs into peripheral tissues as a result 
of  chronic infl ammation, if  the peripheral tissue secretes 
the appropriate homing signals. 
Additionally, immune escape has long been a perplex-
ing property of  cancer cells; MSCs have unique immuno-
logical properties in that they are not immunogenic, they 
do not stimulate alloreactivity, and they escape lysis by cy-
totoxic T cells and natural killer cells[40]. This inherent abil-
ity to evade immune recognition may explain why many 
cancer cells evade the host immune response. 
BMDCs as the origin of epithelial cancer: helicobacter 
induced gastric cancer as a model system
We reasoned that BMDCs, as the ultimate uncommitted 
adult stem cell, might represent the ideal candidate for 
transformation, if  placed in a favorable environment. We 
used the well-described H. felis/C57BL/6 mouse model of  
gastric cancer to test this theory[41]. This model is optimal 
for studying the role of  stem cells in infl ammatory-mediat-
ed cancers because C57BL/6 mice do not develop gastric 
cancer under controlled conditions. With Helicobacter 
infection, however, the gastric mucosa progresses through 
a series of  changes including metaplasia and dysplasia, 
culminating in gastrointestinal intraepithelial neoplasia 
(GIN)[42] by 12-15 mo of  infection, thus reiterating human 
disease, where gastric cancer in the absence of  Helico-
bacter infection is unusual, while longstanding infection 
carries a signifi cant (up to 1-3%) risk of  gastric cancer[43-48]. 
In order to test the role for BMDCs in gastric cancer (Figure 
3), C57BL/6J mice were myeloablated and transplanted 
with gender-mismatched bone marrow from mice that 
expressed a non-mammalian beta-galactosidase enzyme 
[C57BL/6JGtrosa26 (ROSA 26)], mice that expressed green 
fl uorescent protein [C57BL/6J-beta-actin-EGFP (GFP)], or 
control C57BL/6J liter mates. Engraftment of  ROSA26 
BMDCs into the gastric mucosa was confi rmed by several 
independent methods including detecting enzyme activity, 
specifi c B-galactosidase immunohistochemistry (IHC, two 
cytoplasmic markers) (Figures 4 and 5), and detection of  
LacZNeo fusion gene sequence (nuclear marker) by PCR 
within beta-galactosidase positive gastric glands isolated by 
laser capture microscopy. In those mice transplanted with 
GFP marrow, GFP was detected by fl uorescence activated 
cell sorting of  cytokeratin positive-single cell preparations, 
and GFP immunohistochemistry of  tissue sections. X and 
Y chromosome fluorescent in situ hybridization (X and 
Y-FISH) was used as an additional means to detect BM-
DCs in gender mismatched transplants[41]. 
As expected, acute Helicobacter infection was associ-
ated with an infl ux of  bone marrow-derived infl ammatory 
cells (Figure 4A - blue staining) into the tissue. At early 
time points, we did not detect any engraftment or differen-
tiation of  BMDCs to an epithelial cell phenotype. At 20 wk 
of  infection, rare glands entirely replaced by BMDCs were 
isolated, suggesting that engraftment into the stem cell 
niche had occurred. These fi ndings were more pronounced 
at 30 wk, where antralized glands and metaplastic cells at 
the squamocolumnar junction were entirely replaced by 
marrow-derived cells (Figures 4D and E). The severity of  
intraepithelial dysplasia increased over time, and by one 
year of  infection, most mice developed invasive neoplastic 
glands. All of  the intraepithelial neoplasia in mice infected 
Figure 3 An experimental mouse model for bone marrow transplantation and 
H. felis-induced gastric carcinoma.
↓
↓
↓
↓
900 rads
C57BL/6
Transplant with
GFP
ROSA26 or
wt marrow
H. felis  infection
Evaluate for
GFP,
Beta-gal activity and
Y-FISH
366          ISSN 1007-9327      CN 14-1219/ R     World J Gastroenterol      January 21, 2006    Volume 12     Number 3
www.wjgnet.com
for 12-16 mo rose from donor marrow cells, strongly sug-
gesting an inherent vulnerability of  this population of  cells 
to malignant progression. Progressive parietal and chief  
cell loss is a hallmark of  chronic Helicobacter infection. 
Of  the few parietal or chief  cells which we isolated from 
the infected mice, none were derived from the bone mar-
row, strongly suggesting that marrow cells do not differen-
tiate toward the parietal or chief  cell phenotype under the 
experimental conditions that were used[41].
Normal healing of  the gastric mucosa after iatrogenic 
ulceration likewise did not require BMDCs[41], nor did 
loss of  specifi c cell lineages, such as targeted ablation of  
parietal cells, lead to marrow engraftment[41]. Rather, it 
seems that long standing infl ammation and infl ammatory 
mediated damage to the epithelium is required - an envi-
ronment strongly linked to the development of  cancer in 
many settings. In our Helicobacter-gastric cancer model, 
infection and inflammation reached a plateau at 8 wk; 
however, engraftment was not apparent until 20 wk, sug-
gesting that events other than increased infl ammation are 
responsible for engraftment. Between 8 and 20 wk, there 
is loss of  the oxyntic glands, and a restructuring of  the 
gastric architecture to include metaplastic cell lineages, re-
fl ecting the effects of  an abnormal tissue milieu on rapidly 
proliferating cells[49]. Once engraftment began, however, 
the number of  bone marrow-derived glands increased dra-
matically, suggesting that a threshold for recruitment had 
been reached[41]. 
In addition to epithelial cells within the tumor, BMDCs 
also comprise a subset of  cells within the tumor stroma 
and within seemingly uninvolved epithelium and subepi-
thelial spaces adjacent to the tumors. We have recovered 
adipocytes (Figure 5C), fibroblast, endothelial cells and 
myofibroblasts (Figures 4 B and C) derived from bone 
marrow precursors in areas adjacent to dysplasia and neo-
plasia.
Based on these experiments, we have proposed a new 
paradigm for epithelial cancer (Figure 6). Chronic tissue 
infl ammation leads to tissue injury and with time, to tis-
sue stem cell failure. Peripheral stem cell failure leads to 
recruitment and permanent engraftment of  BMDCs into 
the tissue stem cell niche, where the BMDCs essentially 
take over the function of  the tissue stem cell. In the setting 
of  infl ammation, specifi cally with Th1 type cytokines and 
an abnormal tissue environment (for example, one lacking 
chief  and parietal cells), the BMDCs initiate differentia-
A D
B E
C
Figure 4 Engraftment of donor-derived ROSA-26 marrow by x-gal staining. A: Mice transplanted with ROSA 26 marrow and infected with H. felis for 4 wk had donor-derived 
leukocytes (blue) infi ltrating the gastric mucosa, and no engraftment into gland structures. B and C: A higher power view reveals myocytes and myofi broblasts in the sub-
mucosal tissue adjacent to vascular structures (arrows). D: After 30 wk of infection, marked architectural distortion is seen with antralization and appearance of metaplastic 
glands. Entire gland structures are derived from donor marrow (blue staining). Gland shown in panel D (arrow) is shown at higher power in E. 
→
→
→
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tion, but fail to regulate growth programs appropriately 
and progresses through stages of  metaplasia and dysplasia. 
We speculate that the inappropriate retention of  primitive 
growth programs in a stem cell forced to replicate may 
permit survival despite otherwise lethal mutations, thus 
allowing transformation. This new model brings together 
previously unexplained observations regarding the behav-
ior of  cancer, and presupposes that properties inherent to 
cancer such as their resistance to apoptosis, their unlimited 
growth potential and their ability for local spread and dis-
tant metastasis are fundamental to the origin of  the cell, 
rather than traits acquired. The concept of  cancer initia-
tion and promotion can also be viewed within the context 
of  this model. Initiation may represent BMDCs traffi cking 
into the stem cell niche as a result of  tissue stem cell dam-
age. In the absence of  continued infl ammation and injury, 
these engrafted cells may behave in a way indistinguishable 
from endogenous tissue stem cells. Promotion may rep-
resent an additional stimulus received at a later time that 
allows sustained proliferation of  BMDCs and transforma-
tion.
In vitro experiments and animal models supporting the 
BMDC-epithelial cancer model
In addition to the Helicobacter-gastric cancer model, other 
studies have begun to address the role of  BMDCs in can-
cer using various in vitro and in vivo models. For example, 
BMDCs have been shown to localize to a known stem cell 
niche within the epidermis known as the CD34 positive 
bulge region of  the hair follicle, and clonally expand to 
repopulate portions of  the epidermis, functioning as an 
epidermal stem cell[50]. Similar to our fi ndings, engraftment 
of  BMDCs to the stem cell niche is dramatically increased 
with injury severe enough to deplete peripheral stem cells 
in the region. However, these are short-term studies. Lon-
ger term studies utilizing carcinogen exposure will deter-
mine the eventual fate of  these BMDCs, and determine 
if  BMDCs in the stem cell niche behave differently from 
peripheral stem cells occupying the same niche. It is in-
triguing, however, to speculate the ultimate fate of  these 
stem cells given the prevalence of  BMDC-skin carcinoma 
in solid organ recipients (see below). 
In addition to residing in the epithelial stem cell niche, 
bone marrow-derived myofi broblasts have been recovered 
within the colonic subepithelial compartments in both 
mice and human beings[51,52]. Interestingly, Direkze et al. ob-
served that in the IL-10 knockout mouse model of  colitis, 
up to 45% of  subepithelial myofi broblasts were marrow 
derived[52], suggesting that in the setting of  chronic infl am-
mation, damaged tissue is replaced by BMDCs. When the 
same group looked at tumor-associated myofi broblasts and 
fi broblasts, they also found a signifi cant portion of  these 
cells derived from bone marrow cells[51]. It is not clear 
from these data, if  tumors recruit bone marrow cells into 
the stromal compartment or if  resident myofibroblasts 
and fi broblasts derived from marrow contribute to tumor 
formation because of  abnormal signaling behavior.  
Adenocarcinoma of  the distal esophagus (Barretts’ ad-
enocarcinoma) results from refl ux-induced mucosal dam-
age followed by healing with a metaplastic intestinal cell 
lineage. This intestinal metaplasia is prone to malignant 
degeneration and is another ideal model to test the role 
of  BMDCs in infl ammatory-mediated cancers. Using a rat 
model of  Barrett’s metaplasia, a signifi cant contribution of  
BMDCs to the stroma and the metaplastic epithelium has 
been demonstrated, supporting a role for BMDCs in these 
pre-neoplastic lesions[53]. Though these fi ndings have only 
been reported in an abstract form so far, this information 
is especially exciting because it provides evidence of  direct 
BMDC involvement in carcinogenesis from both an ad-
ditional species (rat) and tissue type (esophagus), providing 
A B C
→
Figure 5 Immunohistochemistry for bacterial beta-galactosidase confi rms uniform signal in gastrointestinal neoplasia. Mice developed severe dysplasia and intraepithelial 
neoplasia derived from donor marrow, 12-15 mo after infection with H. felis (A) and (B). Immunohistochemistry for bacterial beta-galactosidase demonstrates cytoplasmic 
staining in dysplastic glands. A population of adipocytes in the submucosa are also stained for beta-galactosidase (arrow).
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Figure 6 A new paradigm proposed for epithelial cancer.
368          ISSN 1007-9327      CN 14-1219/ R     World J Gastroenterol      January 21, 2006    Volume 12     Number 3
www.wjgnet.com
further support for our BMDC-epithelial cancer model. 
Human data supporting the BMDC-epithelial cancer model
In human beings, the incidence of  solid tumors is signifi -
cantly increased following bone marrow transplantation[54] 
and may be related to persistent chronic infl ammation of  
graft vs. host disease. The data on BMDCs in human can-
cers, however, have been confl icting. First, it is diffi cult to 
examine the contribution of  donor marrow to tumor for-
mation in human beings because of  a paucity of  cell mark-
ers to consistently identify autologous BMDCs or donor 
cells after BM transplantation. The most reliable marker 
we have to date is identifi cation of  the sex chromosomes 
in sex mismatched transplants. However, there are inherent 
diffi culties with using Y-chromosome identifi cation. X/Y 
fl uorescent in situ hybridization (FISH) analysis of  archived 
tumors is estimated to miss more than 50% of  Y-positive 
cells due to sectioning bias, where only a portion of  the 
nucleus and thus only a portion of  the chromosomes are 
included in the tissue section. Additionally, females with 
a history of  carrying a male fetus may show peripheral 
blood chimerism confounding interpretation of  data, and 
eliminating this population from the study. Also, tumors 
identifi ed within a short time after transplant may refl ect 
the effects of  immunosuppression on previously unde-
tected early malignancy and not newly formed tumors, and 
may explain why some studies conclude tumors in these 
patients are host derived[55], while other studies demon-
strate a defi nite contribution of  donor’s-BMDCs[56]. Stud-
ies utilizing larger numbers of  patients followed for longer 
periods of  time will better address this new and controver-
sial area, and determine if  the BMDCs are confi ned to the 
stroma, involved in angiogenesis or constitute the epithelial 
component of  the tumor mass in human beings.  
In addition to patients receiving bone marrow trans-
plants, recipients of  solid organ transplants also have a 
higher incidence of  secondary malignancy. Interestingly, 
in solid organ transplant recipients, hematopoietic cells of  
donor origin are often found in the circulation, indicat-
ing that hematopoietic stem cells are transferred with the 
transplanted organ[57,58]. These transferred stem cells have 
been shown to give rise to Kaposi sarcoma (KS), a vascular 
tumor[59], and skin carcinoma[60]. The detected KS lesions 
occurred distal to the graft site, and formed presumably 
via mobilization of  donor progenitor cells with subsequent 
transformation at a distant site. Donor-derived stem cells 
contribute to skin carcinomas, and have been recovered 
as components of  squamous cell carcinoma, basal cell 
carcinoma, actinic keratosis, keratoacanthomas and benign 
cutaneous lesions[60], attesting to the great potential for ab-
normal differentiation of  these cells. BMDCs as terminally 
differentiated cells in other organs including hepatic endo-
thelial cells, hepatocytes and biliary epithelial cells[61], sug-
gesting that these cells may play a role in transformation 
within these organs as well, if  subjected to the appropriate 
environmental conditions.
CONCLUSION
One of  the greatest and most elusive challenges in cancer 
biology has been to identify the cellular origin of  cancer. 
We have identifi ed the bone marrow stem cell as the cell of  
origin of  Helicobacter-induced gastric cancer in a mouse 
model, radically altering our current view of  gastric cancer 
formation in particular, and of  inflammation-mediated 
cancers in general. The concept of  BMDC plasticity is be-
ing increasingly recognized and validated by independent 
groups. Our recent observation that BMDCs are the origin 
of  Helicobacter-induced gastric cancer[41] combined with 
supporting observations of  BMDCs in other tumors such 
as benign and malignant tumors of  the skin[60], Kaposis 
sarcoma[59] Barretts’ adenocarcinoma of  the esophagus[53] 
as well as demonstration of  BMDCs as constituents of  
tumor stroma and tumor vascular structures[52-56] suggests 
exciting approaches for cancer therapy. If  the propen-
sity for BMDCs to transform is based on inappropriate 
regulation of  immature growth programs, with growth 
programs left “turned on” rather than the previously held 
concept of  mutation driven-reactivation of  programs, can 
we target these pathways? Undoubtedly, genetic mutations 
have occurred which are irreversible; but if  we can target 
and switch off  inappropriately activated growth cascades, 
perhaps we can push these damaged cells into apoptosis 
or enhance the sensitivity to conventional chemo- and ra-
diotherapy. These approaches may lead to novel and more 
effi cacious cancer therapy. 
Presently, our laboratory is involved in identifying 
the cell population within the bone marrow capable of  
cancer formation as well as defining the homing and 
differentiation signals which allow these cells to access 
to gastric mucosa, and to differentiate as metaplastic and 
dysplastic cells. Studies designed to determine if  fusion 
is a means of  bone marrow cell integration into gastric 
mucosa and gastric cancer are underway. The applicability 
of  these fi ndings to other epithelial cancers will be tested 
as well as our ability to control the growth of  these cells 
by manipulations of  the local tissue environment. These 
efforts are aimed at identifying cell-specific targets for 
chemotherapy. Findings from these studies will radically 
alter our approach to the treatment of  gastric cancer as 
well as other solid tumors, and offer hope for improved 
survival and potential cure. 
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